دورية أكاديمية

Total skin electron beam radiation therapy for mycosis fungoides.

التفاصيل البيبلوغرافية
العنوان: Total skin electron beam radiation therapy for mycosis fungoides.
المؤلفون: Reddy S; Department of Radiation Oncology, Richard L. Roudebush Veterans Administration Medical Center/Indiana University Medical Center, Indianapolis 46202., Parker CM, Shidnia H, Gaffney MG, Blyton BD, Pruner LM, Kalasinski LA
المصدر: American journal of clinical oncology [Am J Clin Oncol] 1992 Apr; Vol. 15 (2), pp. 119-24.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Lippincott Williams & Wilkins Country of Publication: United States NLM ID: 8207754 Publication Model: Print Cited Medium: Print ISSN: 0277-3732 (Print) Linking ISSN: 02773732 NLM ISO Abbreviation: Am J Clin Oncol Subsets: MEDLINE
أسماء مطبوعة: Publication: Hagerstown, MD : Lippincott Williams & Wilkins
Original Publication: New York, N.Y. : Masson Pub. USA, c1982-
مواضيع طبية MeSH: Mycosis Fungoides/*radiotherapy , Radiotherapy, High-Energy/*methods , Skin Neoplasms/*radiotherapy, Adult ; Aged ; Aged, 80 and over ; Humans ; Middle Aged ; Mycosis Fungoides/pathology ; Neoplasm Recurrence, Local ; Neoplasm Staging ; Radiotherapy Dosage ; Radiotherapy, High-Energy/adverse effects ; Retrospective Studies ; Skin Neoplasms/pathology ; Survival Analysis ; Treatment Outcome
مستخلص: Forty-nine patients with biopsy-proven mycosis fungoides, Stages I-IV were treated using total skin electron beam irradiation (TSEBI). Total dose ranged from 600 cGy to 3,200 cGy. To evaluate the dose response relationship, patients were retrospectively divided into two groups. In Group I, 18 patients received a dose of 2,000 cGy or less, and in Group II, 31 patients received more than 2,000 cGy. The overall response rate was 87.7% with a 75.7% complete response and 12.2% partial response. Complete response was higher among patients with early stage disease: (Stage IA 1/1, Stage IB 23/35 (92%), Stage IIA 3/4 (75%), Stage IIB 4/8 (50%), Stage III 3/6 (50%), Stage IVA 1/1, Stage IVB 0/1, and unstaged group 2/3 (66.6%)). Patients treated with a higher total dose had a higher overall 5-year survival rate (Group I 38%, Group II 68%), longer median duration of complete response (Group I, 27 months; Group II, 35.3 months), slightly better complete response rate (72.2% for Group I, 77.4% for Group II), and lower recurrence rate (Group I, 94%; Group II, 83.9%) compared to patients with lower total dose. Complications from TSEBI were minimal. Total skin electron beam irradiation is effective in controlling early stage mycosis fungoides; however, a prospective study to evaluate optimum total dose is needed.
تواريخ الأحداث: Date Created: 19920401 Date Completed: 19920429 Latest Revision: 20190902
رمز التحديث: 20231215
DOI: 10.1097/00000421-199204000-00005
PMID: 1553898
قاعدة البيانات: MEDLINE
الوصف
تدمد:0277-3732
DOI:10.1097/00000421-199204000-00005